Gå til hovedinnhold

SwedenSwedenEpisurf Medical AB B
(EPIS B)

· Nasdaq Stockholm
· Valuta i SEK
Nasdaq Stockholm
Siste
0,810
I dag %
+5,19%
I dag +/-
+0,040
Kjøp
0,810
Selg
0,810
Høy
0,839
Lav
0,722
Omsetning (Volum)
290 519
· Nasdaq Stockholm
· Valuta i SEK
Nasdaq Stockholm
· Nasdaq Stockholm · Valuta i SEK
· Valuta i SEK
Nasdaq Stockholm
Siste
0,810
Utvikling i dag
+5,19%
+0,040
Kjøp
0,810
Selg
0,810
Høy
0,839
Lav
0,722
Omsetning (Volum)
290 519
Kvartalsrapport (Q4)
48 dager siden11min
0,00 SEK/aksje

Ordredybde

Stengt
Antall
Kjøp
1 365
Selg
Antall
1 000

Siste handler

TidPrisAntallKjøpereSelger
635--
365--
10 000--
60--
3--
Volumvektet snittpris (VWAP)
0,776
Volumvektet snittpris (VWAP)
0,776
Omsetning (SEK)
225 644

Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.

Meglerstatistikk

Mest nettokjøp

Mest nettokjøp
MeglerKjøptSolgtNettoInternt
Anonym290 519290 51900

Mest nettosalg

Mest nettosalg
MeglerKjøptSolgtNettoInternt
Anonym290 519290 51900

Selskapshendelser

Kommende
2023 Generalforsamling
9. apr.
Historisk
2023 Kvartalsrapport (Q4)9. feb.
2023 Kvartalsrapport (Q3)27. okt. 2023
2023 Kvartalsrapport (Q2)14. juli 2023
2022 Generalforsamling2. mai 2023
2023 Kvartalsrapport (Q1)28. apr. 2023
Data hentes fra Millistream, Quartr

Relaterte produkter

Ingen Nordnet Markets -sertifikater er tilgjengelig med det underliggende verdipapiret. Vis andre -sertifikater

Kunder besøkte også

Nyheter og Analyser

Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q4)
48 dager siden11min

Nyheter og Analyser

Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.

Selskapshendelser

Kommende
2023 Generalforsamling
9. apr.
Historisk
2023 Kvartalsrapport (Q4)9. feb.
2023 Kvartalsrapport (Q3)27. okt. 2023
2023 Kvartalsrapport (Q2)14. juli 2023
2022 Generalforsamling2. mai 2023
2023 Kvartalsrapport (Q1)28. apr. 2023
Data hentes fra Millistream, Quartr

Relaterte produkter

Ingen Nordnet Markets -sertifikater er tilgjengelig med det underliggende verdipapiret. Vis andre -sertifikater

Shareville

Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
  • 22. okt. 2023
    22. okt. 2023
    Nogle bud på hvad man kan forvente af regnskabet?
    5. des. 2023
    5. des. 2023
    Doesn't look that bad now but it'll take a long time to be a big player in their field.
  • Man skal ikke bli forelsket i en aksje men det er vel lov med litt mancrush på vd? https://twitter.com/palryfors/status/1476680079405199364
  • The Q2 report was essentially in line with our expectations. Episurf plans to file for a 510(k) clearance in the US in Q4 for the Patellofemoral implant system. There have been some delays in the EPIC knee trial and we have pushed the completion and subsequent launch back c1 year (launch in the US in 2025). We have lifted our fair value for the shares to SEK2.7-8.2 (previously SEK2.5-8). Q2 report essentially in line with our expectations. The company reported revenues of SEK2.1m (our estimate: cSEK2m). Product sales were cSEK2m (our estimate: cSEK1.9m). Sales were up by c233% YOY but Q2 last year was hurt by the pandemic outbreak. Overall costs were essentially in line with our estimates and at quarter-end, the company had cSEK121m in cash on the balance sheet. New markets added to the sales organisation. During H1, the company added several new distributor markets to its sales organisation. Among others, the company struck agreements in Australia, New Zealand, Portugal, and Spain. In addition, it recently announced a distribution agreement in the UK to complement its own sales reps. It also hired a sales rep in the Benelux region. EPIC Knee trial delayed. We believe the EPIC knee trial (the US PMA trial for the Episealer Implant System) is delayed. The combination of the pandemic and too-strict inclusion criteria for the trial appear to have made it hard to recruit patients. However, protocol amendments should be in place during the autumn and all paperwork (ethics committees, etc) should be completed so new patients could be operated on according to the amended protocol in Q4 this year. We estimate that this has led to a c1 year delay from our original forecast to get the implant system approved and launched in the US. Might reach the US market in 2022. Despite the delay in EPIC knee, we believe the Patellofemoral implant product could reach the market in the US next year, as this product needs only a 510(k) clearance and the company plans to submit the application in Q4 this year (normally a 90-day process). We believe the company will hire a few staff in a US subsidiary but work mainly with one or more of the independent distributor networks available in the US. New fair value of SEK2.7-8.2/share. We believe the company is moving in the right direction, with growth in its clinical documentation set to continue into 2022. The new patella implant product could add revenues earlier than previously forecast and allow entry into the US market sooner than with the Episealer implant system. We believe its financial position is stable, and its cash should take it into 2023. Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_178712.pdf&Sid=1-7XT0MIJ) Best regards
  • Episurf Medical (NASDAQ: EPIS B) today announces that the development of the companys Episealer Patellofemoral System is progressing according to plan. The previously communicated plan to submit a 510(k) application before the end of the year to the US FDA for US market clearance is still valid. The design for the system is now set and final device testing is presently being conducted. Episealer Patellofemoral System is an implant system with two implants for treatment of chondral and osteochondral lesions in the knee joint. Simultaneously, the company is preparing for a commercial launch in the US of the Episealer Patellofemoral System during 2022. Our excitement about this project is growing as we are approaching filing of the 510(k) as well as the subsequent commercialisation in the US market. We will then enter the largest orthopaedic market in the world, which will be a tremendous milestone for us, comments Pål Ryfors, CEO Episurf Medical. For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com
  • Episurf Medical hereby invites you to a webcasted presentation in connection with the publishing of the Q2 report, the second quarterly report for the fiscal year 2021. The report will be published at 08.30 (CEST) on July 16[th] and available as of this time at www.episurf.com. The presentation will be held in English by CEO Pål Ryfors, and afterwards questions are invited. Date: July 16[th] 2021 Start time: 10:00 (CEST) Location: https://www.finwire.tv/webcast/episurf/episurf-q2-2021/ An on-demand version of the webcast will be available at Episurf Medicals website after closing of the presentation. Questions are welcome in advance by e-mail to: ir@episurf.com. For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Kvartalsrapport (Q4)
48 dager siden11min
0,00 SEK/aksje

Nyheter og Analyser

Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
0,00 SEK/aksje

Shareville

Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
  • 22. okt. 2023
    22. okt. 2023
    Nogle bud på hvad man kan forvente af regnskabet?
    5. des. 2023
    5. des. 2023
    Doesn't look that bad now but it'll take a long time to be a big player in their field.
  • Man skal ikke bli forelsket i en aksje men det er vel lov med litt mancrush på vd? https://twitter.com/palryfors/status/1476680079405199364
  • The Q2 report was essentially in line with our expectations. Episurf plans to file for a 510(k) clearance in the US in Q4 for the Patellofemoral implant system. There have been some delays in the EPIC knee trial and we have pushed the completion and subsequent launch back c1 year (launch in the US in 2025). We have lifted our fair value for the shares to SEK2.7-8.2 (previously SEK2.5-8). Q2 report essentially in line with our expectations. The company reported revenues of SEK2.1m (our estimate: cSEK2m). Product sales were cSEK2m (our estimate: cSEK1.9m). Sales were up by c233% YOY but Q2 last year was hurt by the pandemic outbreak. Overall costs were essentially in line with our estimates and at quarter-end, the company had cSEK121m in cash on the balance sheet. New markets added to the sales organisation. During H1, the company added several new distributor markets to its sales organisation. Among others, the company struck agreements in Australia, New Zealand, Portugal, and Spain. In addition, it recently announced a distribution agreement in the UK to complement its own sales reps. It also hired a sales rep in the Benelux region. EPIC Knee trial delayed. We believe the EPIC knee trial (the US PMA trial for the Episealer Implant System) is delayed. The combination of the pandemic and too-strict inclusion criteria for the trial appear to have made it hard to recruit patients. However, protocol amendments should be in place during the autumn and all paperwork (ethics committees, etc) should be completed so new patients could be operated on according to the amended protocol in Q4 this year. We estimate that this has led to a c1 year delay from our original forecast to get the implant system approved and launched in the US. Might reach the US market in 2022. Despite the delay in EPIC knee, we believe the Patellofemoral implant product could reach the market in the US next year, as this product needs only a 510(k) clearance and the company plans to submit the application in Q4 this year (normally a 90-day process). We believe the company will hire a few staff in a US subsidiary but work mainly with one or more of the independent distributor networks available in the US. New fair value of SEK2.7-8.2/share. We believe the company is moving in the right direction, with growth in its clinical documentation set to continue into 2022. The new patella implant product could add revenues earlier than previously forecast and allow entry into the US market sooner than with the Episealer implant system. We believe its financial position is stable, and its cash should take it into 2023. Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_178712.pdf&Sid=1-7XT0MIJ) Best regards
  • Episurf Medical (NASDAQ: EPIS B) today announces that the development of the companys Episealer Patellofemoral System is progressing according to plan. The previously communicated plan to submit a 510(k) application before the end of the year to the US FDA for US market clearance is still valid. The design for the system is now set and final device testing is presently being conducted. Episealer Patellofemoral System is an implant system with two implants for treatment of chondral and osteochondral lesions in the knee joint. Simultaneously, the company is preparing for a commercial launch in the US of the Episealer Patellofemoral System during 2022. Our excitement about this project is growing as we are approaching filing of the 510(k) as well as the subsequent commercialisation in the US market. We will then enter the largest orthopaedic market in the world, which will be a tremendous milestone for us, comments Pål Ryfors, CEO Episurf Medical. For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com
  • Episurf Medical hereby invites you to a webcasted presentation in connection with the publishing of the Q2 report, the second quarterly report for the fiscal year 2021. The report will be published at 08.30 (CEST) on July 16[th] and available as of this time at www.episurf.com. The presentation will be held in English by CEO Pål Ryfors, and afterwards questions are invited. Date: July 16[th] 2021 Start time: 10:00 (CEST) Location: https://www.finwire.tv/webcast/episurf/episurf-q2-2021/ An on-demand version of the webcast will be available at Episurf Medicals website after closing of the presentation. Questions are welcome in advance by e-mail to: ir@episurf.com. For more information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.

Ordredybde

Stengt
Antall
Kjøp
1 365
Selg
Antall
1 000

Siste handler

TidPrisAntallKjøpereSelger
635--
365--
10 000--
60--
3--
Volumvektet snittpris (VWAP)
0,776
Volumvektet snittpris (VWAP)
0,776
Omsetning (SEK)
225 644

Det er viktig at du er klar over at aksjemarkedet kan både øke og minke i verdi. Selv om sparing i aksjer historisk sett har gitt god avkastning over tid, er det ingen garanti for fremtidig utvikling. Det er alltid en risiko for at du ikke får tilbake pengene du har investert.

Meglerstatistikk

Mest nettokjøp

Mest nettokjøp
MeglerKjøptSolgtNettoInternt
Anonym290 519290 51900

Mest nettosalg

Mest nettosalg
MeglerKjøptSolgtNettoInternt
Anonym290 519290 51900

Kunder besøkte også

Selskapshendelser

Kommende
2023 Generalforsamling
9. apr.
Historisk
2023 Kvartalsrapport (Q4)9. feb.
2023 Kvartalsrapport (Q3)27. okt. 2023
2023 Kvartalsrapport (Q2)14. juli 2023
2022 Generalforsamling2. mai 2023
2023 Kvartalsrapport (Q1)28. apr. 2023
Data hentes fra Millistream, Quartr

Relaterte produkter

Ingen Nordnet Markets -sertifikater er tilgjengelig med det underliggende verdipapiret. Vis andre -sertifikater